This section allows identifying the facility, this information is important for data quality follow up. Source of Standard. Source of Standard

Similar documents
2007 New Data Items. Slide 1. In this presentation we will discuss five new data items that were introduced with the 2007 MPH Coding Rules.

4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines

WHI Extension Appendix A, Form Report of Cancer Outcome (Ver. 8.2) Page 1

WHI Extension Section 8 Outcomes Page 8-85

I.2 CNExT This section was software specific and deleted in 2008.

Format Of ICD-O Terms In Numerical List Each topographic and morphologic term appears only once The first listed term in Bold Type is the Preferred Te

ICD-O CODING Third Edition

Not For Sale. Alternative Billing Codes (ABC Codes) Clinical Care Classification (CCC) System

APPENDIX I. Free-Standing Radiation Therapy Centers Cancer Case Identification Program

Part VIII Entering Information Into the Urology Report Form

Instructions for Coding Grade for 2014+

Changes to SEER Data Set for Scope of Regional Lymph Node Surgery

CODING PRIMARY SITE. Nadya Dimitrova

A Comprehensive Approach to. International Cancer Survival Benchmarking. SurvMark-2

The European Commission s science and knowledge service. Joint Research Centre

7/29/ Grade Coding Instructions ICD-O-3 Updates. Outline. Introduction to Coding Grade for 2014+

DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #

Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual

INTRODUCTION TO CANCER STAGING

CODING TUMOUR MORPHOLOGY. Otto Visser

Greater Baltimore Medical Center Sandra & Malcolm Berman Cancer Institute

AJCC TNM 6 th Edition Staging Input Data Dictionary

NAACR Treatment Webinar Quiz 1

Introduction to ICD-O-3 coding rules

FINALIZED SEER SINQ S MAY 2012

1. Laterality, Primary Site E:Lateral & Site conflict Laterality (295) = 0 _ 2 Primary Site (291) = C711 Date of Diagnosis (283) =

CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I

The Components of an Abstract. Alfreda Woods, BS, CHES, CTR Program Manager, DCCR DelMarVa-DC Educational Conference October 12, 2018

Different Types of Cancer

CERVIX MEASURE SPECIFICATIONS

NAACCR Webinar Series 1

Web Plus Instructions Radiation CCR

Canadian Cancer Registry Reference Guide For Years

Table of contents. Page 2 of 40

We re on the Web! Visit us at VOLUME 19 ISSUE 1. January 2015

Tumor Comparison. NAACCR Death Clearance Manual Update. Bobbi Jo Matt, BS RHIT CTR NAACCR 2013 Conference, Austin, TX June 12, 2013

QUICK-START GUIDE NCDB Participant Use File (NCDB PUF)

Outline. How to Use the AJCC Cancer Staging Manual, 7 th ed. 7/9/2015 FCDS ANNUAL CONFERENCE ST PETERSBURG, FLORIDA JULY 30, 2015.

Who What When Where Why. Case Finding 5 W s. NAACCR Webinar Series. Presented by: Joyce L. Jones, CTR Professional Registry Services, LLC

Q&A Session NAACCR Webinar Series Collecting Cancer Data: Pancreas January 05, 2012

Lung Cancer and Mesothelioma Site Specific Clinical Reference Group Data Quality Report 2009

REPORTABLE CASES MISSISSIPPI For cases diagnosed 10/1/2015 and after

VULVAR CARCINOMA. Page 1 of 5

Collaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ]

Cheryl Ericson, MS, RN, CCDS, CDIP, AHIMA Approved ICD 10 CM/PCS Trainer Clinical Documentation Program Manager for ezdi.

California Cancer Registry Production Automation and Quality Control Unit Data Alert - Registrar

Mississippi Cancer Registry Reporting Manual Revised 2016

ICD-O CODING Third Edition

CASEFINDING. Debra W. Christie, MBA, RHIA, CTR, CCRP Director, Cancer Research & Data Center University of Mississippi Medical Center

2010 Cancer Data Collection Updates: Standards Volume II, Introduction. What s New for 2010

MCR: MANAGEMENT OF 2018 CHANGES. By: Maricarmen Traverso-Ortiz MPH, CGG, CTR

Kyle L. Ziegler, CTR. California Cancer Registry U.C. Davis Health System

Introduction & Descriptors

NAACCR Webinar Series 1

OSCaR UPDATE. Manager s Update Donald Shipley, MS. Oregon State Cancer Registry

46. Merkel Cell Carcinoma

Reporting of Cancer Stage Information by Acute Care Hospitals in Ontario

Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint

AJCC 8 th Edition Staging. Introduction & Descriptors. Learning Objectives. This webinar is sponsored by

Pathology of Sarcoma ELEANOR CHEN, MD, PHD, ASSISTANT PROFESSOR DEPARTMENT OF PATHOLOGY UNIVERSITY OF WASHINGTON

Interactive Staging Bee

Kentucky Cancer Registry Spring Training 2017

1. Laterality, Primary Site E:Lateral & Site conflict Laterality (295) = 0 _ Primary Site (291) = C711 Date of Diagnosis (283) =

Chapter 3. Neoplasms. Copyright 2015 Cengage Learning.

What s New for 8 th Edition

Thyroid nodules - medical and surgical management. Endocrinology and Endocrine Surgery Manchester Royal Infirmary

Collecting Cancer Data: Hematopoietic & Lymphoid Neoplasms

Seventh Edition Staging 2017 Breast

Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual

Classification of Hematologic Malignancies. Patricia Aoun MD MPH

Setting the stage for change: upgrading the physician cancer case reporting application in New York

FINALIZED SEER SINQ S NOVEMBER 2011

Cancer as a Disease. Linda D. Rego, CTR March 2009

Patient Identification Quiz

AJCC 8 th Edition Staging. Introduction & Descriptors. Learning Objectives. This webinar is sponsored by

Acute: Symptoms that start and worsen quickly but do not last over a long period of time.

2010 Hematopoietic and Lymphoid ICD-O Codes - Alphabetical List THIS TABLE REPLACES ALL ICD-O-3 Codes

2012 Hematopoietic and Lymphoid ICD-O Codes - Numerical List THIS TABLE REPLACES ALL ICD-O-3 Codes

Question. Lillian Sung MD, PhD. The Hospital for Sick Children. February 10, 2017

Cancer in Estonia 2014

Pathology Report Patient Companion Guide

CASEFINDING. KCR Abstractor s Training

Q: How do you clinically code the N if the nodes are stated to be positive on mammogram/us or other imaging? No biopsy of nodes was done.

Thyroid Gland. Protocol applies to all malignant tumors of the thyroid gland, except lymphomas.

Requirements for Abstracted Text

ENCR Call for Data 21 May 2010

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

Q&A Session Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms Thursday, November 6, 2014

2015 Patient Outcomes Report

Cancer Programs Practice Profile Reports (CP 3 R) Rapid Quality Reporting System (RQRS)

Thyroid and Adrenal Gland

Neoplasia part I. Dr. Mohsen Dashti. Clinical Medicine & Pathology nd Lecture

Non-Hodgkin Lymphoma. Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract.

NEW JERSEY STATE CANCER REGISTRY

Contents. vii. Preface... Acknowledgments... v xiii

Commission on Cancer Updates

Lesson 8 Classifications

Transcription:

Data Dictionary Case Administration This section allows identifying the facility, this information is important for data quality follow up Facility Name This identifier is needed to evaluate This data item is automatically reporting per facility and for data populated through the username quality purposes Facility License Number quality purposes and password the user This identifier is needed to evaluate This data item is automatically reporting per facility and for data populated through the username Data Entered By and password the user This identifier is needed for This data item is automatically communication purposes related to populated through the username data cleaning and training and password the user Facility From Facility name as per HAAD facility licensing system Upper cases only, left justified, space allowed, No other special characters Facility License number as per HAAD facility licensing system Alphanumeric Facility License number as per HAAD facility licensing system Upper cases only, left justified, space allowed, No other special characters Data Format Alphabet 40 Data Format Any 10 combina tion, Data Format Alphabet 40 Data Format

This data items enables the central Select the name the facility from registry to understand referral which the patient came to yours, if patterns in the catchment area, it is that patient was a referred one also helpful for data completeness. Facility To This data items enables the central Select the name the facility to registry to understand referral which the patient is referred. patterns in the catchment area, it is also helpful for data completeness. Select the name one facility Drop List 255 Data Format Select the name one facility Drop List 255 Patient Information This section encompasses mainly demographic data necessary to identify the cases for data cleaning and linkage. First Name Patient Identification tool record the name as per patient file or identity card if available, if patient has two names as first name, put them both in this data field Middle Name Record the name as per patient file or identity card if available, if patient has two names as first name, put them both in this data field Upper cases only, no embedded spaces, left justified, blank filled. No space, hyphen, coma or other special characters Data Format Alphabet Truncate if more than 40 characters Data Format 2

Patient Identification tool Last Name record the name as per patient file or identity card if available, if patient has two names as first name, put them both in this data field Patient Identification tool record the name as per patient file or identity card if available, if patient has two names as first name, put them both in this data field Emirates ID Number Required e- This ID is unique for each patient; it helps all systems to identify the patient for data cleaning, linkage and analysis. It is vital in distinguishing patients similar names Put this number as per the Emirates ID card Medical Record Number Record the name as per patient file or identity card if available, if patient has two names as first name, put them both in this data field Upper cases only, no embedded spaces, left justified, blank filled. No space, hyphen, coma or other special characters Record the name as per patient file or identity card if available, if patient has two names as first name, put them both in this data field Upper cases only, no embedded spaces, left justified, blank filled. No space, hyphen, coma or other special characters Data Format Alphabet 000-0000-0000000-0 National without card 111-1111-1111111-1 Expatriate resident without a card 222-2222-2222222-2 Non national, non-expat resident without a card 999-9999-9999999-9 Unknown status, without a card Any 15 digits Alphabet Data Format 3 Trunca te more than 40 if charac ters Truncate if more 40 than characters Numeric 15 Data Format

It helps identifying the patient within Put the medical record number as Any Combination Alphanu 11 the facility. This is necessary for follow per your facility policies. meric, up, data quality and clinical research uppercas purposes e and Address at Diagnosis - City numbers It allows for the analysis cancer clusters or environmental studies. It also helps understanding referral patterns Address at Diagnosis - Emirate Name the city in which the patient resides at the time the reportable tumor was diagnosed. If the patient has multiple primaries, the address might be different for subsequent primaries. Don't update the information if the patient's address changed after diagnosis. Don't record the city the facility where the diagnosis took place. Abu Dhabi Al Ain Al Ain Industrial Area Al Jemi Al Khabesi Al Khatim Al Mafraq Al Mirfa Al Rahba Al Ruwais Al Yahar Baniyas Delma Ghayathi Liwa Madinat Zayed Mussafah Shahama Sila Description 4

It allows for the analysis cancer clusters or environmental studies. It also helps understanding referral patterns Date Birth Name the Emirate in which the patient resides at the time the reportable tumor was diagnosed. If the patient has multiple primaries, the address might be different for subsequent primaries. Don't update the information if the patient's address changed after diagnosis. Date birth identifies the day, month and year when the patient was born. Together with the date diagnosis, it is used to calculate the age at diagnosis This information helps identifying the patient It is included in analysis based on age cohort If you have only the age and date diagnosis, then calculate the year birth. Month and day birth are recorded as June 15th. If you have the year birth but not the month or day, then unknown month birth shall be June, and unknown day birth shall be 15. Date Birth - Check If Date Is Incomplete Identify incomplete dates for statistical analysis Gender Check only if you don t have the exact information about day or month birth Abu Dhabi Ajman Dubai Fujairah Ras al Khaimah Sharjah Um Al Quwain Other DDMMYYYY Date 8 Check box Date 1 5

To identify the sex the patient. This Record as provided in the patient Male item is necessary to compare cancer medical file, or the identity card. This Female sites between genders data item should have the same value Nationality in case multiple primaries. Identify distribution cancer among Record as per the patients Countries data set different nationalities Marital status identification card or passport To identify the current marital status the patient Also helps identifying the patient once accompanied to other identifiers Record as provided in the patient medical file, or the identity card. This data item Should have the same value in case multiple primaries. 1 =Single 2= Married 3= Divorced 4= Widowed Description Occupation (longest) 5= Not Known This data helps identifying Put the occupation that the patient HAAD occupation list environment related risk factor. An had for most his life, don't put the essential element in cancer current employment, unless this is prevention the longest occupation. If not listed, use "Other" Cancer Information 6

This section includes basic clinical data about the disease. Date Initial Contact / Admission This date helps measuring the period between the initial contact and the start treatment for quality indicators Date Initial Diagnosis Record the date when the patient had first contact with the facility, in or out patient, for diagnosis or treatment reportable tumor. In case diagnosis by autopsy, then this date is the date death This date is necessary in the survival calculations as start point Date initial diagnosis by a recognized medical practitioner for the tumor being reported whether clinically or microscopically confirmed. Regardless whether the diagnosis was made at the reporting facility or elsewhere. Date Initial Diagnosis - Check If Date Is Incomplete Identify incomplete dates for statistical analysis Multiplicity Counter Check only if you don t have the exact information about day or month diagnosis DDMMYYYY Date 8 DDMMYYYY Date 8 Check box Date 1 Data Format 7

It is used to count the number tumors (multiplicity) reported as a single primary. Use the IARC multiple primary rules for the specific site to determine whether the tumors are a single primary or multiple primaries Code the number tumors being abstracted as a single primary Do not count metastasis. When there is a tumor or tumors with separate single or multiple foci, ignore/do not count the foci. Use code 01 when: o There is a single tumor in the primary site being abstracted o There is a single tumor with separate foci tumor Use codes 00-04 and code 99 for solid tumors including the following sites and histologies: Dendritic cell sarcoma (9757) Follicular dendritic cell sarcoma, extranodal (9758) Histiocytic sarcoma (9755) Ill-defined sites (C760-C768) Interdigitating dendritic cell sarcoma (9757) Kaposi sarcoma (9140) Langerhans cell histiocytosis (9751) Langerhans cell sarcoma (9756) Lymphoma, extranodal primary site (9590-9729, 9735-9738) Malignant histiocytosis (9750) Mast cell sarcoma (9740) Myeloid sarcoma (9930) Plasmacytoma, extramedullary (9734) Plasmacytoma, solitary (9731) Use code 88 for: Leukemia (9800-9920, 9931-9948, 9963, 9964) 00 No primary tumor identified 01 One tumor only 02 Two tumors present 03 Three tumors present 04 Four tumors present 88 Information on multiple tumors not collected/not applicable for this site 89 Multicentric, multifocal, number unknown 99 Unknown if multiple tumors; not documented 8

Lymphoma, lymph nodes or bone marrow primary site (9590-9729, 9735-9738) Immunoproliferative diseases and other hematopoietic neoplasms (9732, 9733, 9741, 9742, 9759-9762, 9764, 9950, 9960-9962, 9965-9967, 997, 9975, 9980, 9982-9987, 9989, 9991. 9992) Unknown primary (C809) Use code 89 when: The tumor is described as multifocal or multicentric and the number tumors is not mentioned Use code 99 when: The original pathology report is not available and the documentation does not specify whether there was a single or multiple tumors in the primary site The tumor is described as diffuse The operative or pathology report describes multiple tumors but does not give an exact number It is unknown if there is a single tumor or multiple tumors and the multiple primary rules instructed you to default to a single tumor. Primary Site / ICDO-3 This information is the basis staging and treatment This information is the basis cancer classification and stratification Primary Site - Text Refer to ICDO-3 Topography coding rules to code for the site the origin Consult the physician to identify the primary site if that information was not available for you. C000-C809, Refer to ICDO-3 Alphanumeric, C followed by 3 digits, no special characters, no embedded blanks 9 5

This information is needed for quality coding and data cleaning Histology / ICDO-3 Put the exact wording used by the physician to describe the diagnosis Identify the type tissues the primary site, it is the basis for staging Can affect disease prognosis. This data item is necessary for the decision on multiple primaries Histology - Text Refer to ICDO-3 Morphology coding rules to code for the histology Code using the final pathology report The code for Cancer, NOS (8000) and Carcinoma (8010) are not interchangeable, if the physician writes Carcinoma, then code histology as 8010 This information is needed for quality coding and data cleaning Behavior / ICDO-3 Put the exact wording used by the pathologist to describe the cell type Behavior identifies whether the tumor is benign or malignant Grade / ICDO-3 Code 3 for any malignancy present, even in metastatic nodes beyond the primary site Any text Text Field 255 8000-9989, Refer to ICDO-3 Alphanumeric, C 5 followed by 3 digits, no special characters, no embedded blanks Any text Text Field 255 2 = Carcinoma in situ Numeric 1 3 = Malignant, Primary site Data Format 10

(Differentiation) It describes how far the tumor cells resemble the normal cells, important information for prognosis Laterality Code using the last pathology report prior to treatment. In case pathology report providing two grades, code for the highest. If no pathology report available, use imaging reports. If the primary site is unknown, code grade as 9. Use codes 5-8 for leukemia and lymphoma, don't use grades 1-4, and don't code for lymphoma using "high grade", or "low grade" as they don't refer to differentiation, use only codes 5-8 Code for the side a paired organ, or the side the body on which the reportable tumor originated. This applies to the primary site only. Basis Diagnosis Record the side the paired organ from which the primary was originated. Don't record metastatic site as bilateral involvement. It gives information about the precision diagnosis, In case multiple diagnostic methods, code for the most definitive method. 1= Grade I: Well differentiated 2= Grade II: Moderately differentiated 3= Grade III: Poorly differentiated 4= Grade IV: Undifferentiated/ Anaplastic 5= T cell/t-precursor 6= B cell/ pre-b/ B-precursor 7= Null cell/ non T-non B 8= NK (natural killer) cell 9= Grade not determined/ not stated/ not applicable 0= Not a paired site, Not Applicable 1= Right: origin primary 2= Left: origin primary 3= Only one side involved, right or left origin unspecified 4= Bilateral involvement 5= Paired site: midline tumor 9= Paired site, but lateral origin unknown Positive Histology Positive Cytology Numeric 1 11

and case finding process Class Case To differentiate between Choose the case that corresponds exactly analytical and nonanalytical to your patient relationship with the cases facility Staging and First Course Treatment Positive microscopic confirmation, method not specified Positive laboratory test/marker study Direct visualization without microscopic confirmation Radiology and other imaging techniques without microscopic confirmation Clinical diagnosis only Unknown whether or not microscopically confirmed, death certificate only First Diagnosed at the reporting facility and all the first line treatment was done elsewhere First diagnosed and all or part the first line treatment done at the reporting facility First Diagnosed elsewhere, and al or part the first line treatment was done at the reporting facility First Diagnosed and all or part the first line treatment was done elsewhere First diagnosed by autopsy Diagnosis by death certificate onl Unknown TNM stage, basic information about first line treatment and few follow up data 12

Clinical T Site specific code that evaluates the Code Clinical T as per treating X primary tumor clinically (T) and physicians' notes. If the 0 reflects the tumor size and/or physician did not record that, IS extension as recorded. Clinical stage is then the registrar can code for A assigned prior to any cancer-directed Clinical T with the available 1 treatment and should not be changed clinical data. Use AJCC 7th 1A based on subsequent information edition. Use X for absent values 1B 1C 1D 1MI 2 2A 2B 2C 2D 3 3A 3B 3C 3D 4 4A 4B 4C 4D 4E 13

Not applicable Clinical N Unknown Site specific code that evaluates the Code Clinical N as per treating X involvement lymph nodes. Clinical physicians' notes. If the 0 stage is assigned prior to any cancer- physician did not record that, 1 directed treatment and should not be then the registrar can code for 1A changed based on subsequent Clinical N with the available 1B information clinical data. Use AJCC 7th 1C edition. Use X for absent values 1MI 2 2A 2B 2C 3 3A 3B 3C 4 Not applicable Clinical M Unknown Site specific code that evaluates the Code Clinical M as per treating X spread cancer to other sites. Clinical physicians' notes. If the 0 14

stage is assigned prior to any cancer- physician did not record that, 1 directed treatment and should not be then the registrar can code for 1A changed based on subsequent Clinical M with the available 1B information clinical data. Use AJCC 7th 1C edition. Use X for absent values 1D 1E Not applicable Unknown Clinical Stage Group Identify the extent the disease Code Clinical Stage Group as 0 based on T, N, and M values. it is used per treating physicians' notes. 0A for treatment planning and evaluation If the physician did not record 0IS outcomes that, then the registrar can 1 code for it with the available 1A clinical data. Use AJCC 7th 1B edition. Use X for absent values 1C 1S 2 2A 2B 2C 3 3A 3B 3C 4 15

4A 4B 4C Occult Not applicable Pathological T Unknown Site specific code that evaluates the Code Pathological T as per X primary tumor Pathologically (T) and Pathology report. 0 reflects the tumor size and/or IS extension as recorded. Pathological A stage is assigned prior to any cancer- 1 directed treatment and should not be 1A changed based on subsequent 1B information 1C 1D 1MI 2 2A 2B 2C 2D 3 3A 3B 3C 3D 16

4 4A 4B 4C 4D 4E Not applicable Pathological N Unknown Site specific code that evaluates the Code Pathological N as per X involvement lymph nodes Pathology report. 0 1 1A 1B 1C 1MI 2 2A 2B 2C 3 3A 3B 3C 4 Not applicable Unknown 17

Pathological M Site specific code that evaluates the Code Pathological M as per X spread cancer to other sites. Pathology report. 0 1 1A 1B 1C 1D 1E Not applicable Pathological Stage Group Unknown Identify the extent the disease Code pathological Stage 0 based on T, N, and M values. it is used Group as per pathology report. 0A for treatment planning and evaluation 0IS outcomes 1 1A 1B 1C 1S 2 2A 2B 2C 18

Cancer Directed Surgery This information is used to evaluate and compare treatment options Start Date (Surgery) This data can be found in the surgery reports. Document the most invasive surgery conducted on the primary site as first line (course) treatment. Record here excisional biopsies that remove the whole site. If a previous surgery was done to remove part the primary site, followed by another final procedure, then record the final procedure. Any procedures were provided to alleviate symptoms or prolong life should not be recorded here. If the currently available information were not complete, then a follow up effort should be conducted to complete the information. It records the sequence multiple treatment modalities This data can be found in the surgical reports. Record the date the most curative surgery conducted on 3 3A 3B 3C 4 4A 4B 4C Occult Not applicable Unknown Permissible Values Yes/No Permissible Values DDMMYYYY Date 8 19

Radiation Therapy the primary site. If a previous surgery was done to remove part the primary site, followed by another final procedure, then record the date the final procedure This information is used to evaluate Only primary site directed radiation therapy provided and compare treatment options Start Date (Radiation Therapy) as first line treatment should be recorded It records the sequence multiple This data can be found in the radiation oncologist treatment modalities summary or notes Permissible Values Yes/No Permissible Values DDMMYYYY Date 8 Chemotherapy Permissible Values This information is used to evaluate Only primary site directed chemotherapy provided as Yes/No and compare treatment options Start Date (Chemotherapy) first line treatment should be recorded Permissible Values It records the sequence multiple This data can be found in the physician notes and DDMMYYYY Date 8 treatment modalities Hormonal Therapy discharge summary Permissible 20

Values This information is used to evaluate Only primary site directed Hormonal therapy provided Yes/No and compare treatment options Start Date (Hormonal Therapy) as first line treatment should be recorded Permissible Values It records the sequence multiple This data can be found in the physician notes and DDMMYYYY Date 8 treatment modalities Immune Therapy discharge summary Permissible Values This information is used to evaluate Only primary site directed immune therapy provided Yes/No and compare treatment options Start Date (Immune Therapy) as first line treatment should be recorded Permissible Values It records the sequence multiple This data can be found in the physician notes and DDMMYYYY Date 8 treatment modalities discharge summary Hematologic Transplant and Endocrine Procedure Permissible Values This information is used to evaluate Only primary site directed procedures provided as first Yes/No and compare treatment options Start Date (Hematologic) line treatment should be recorded Permissible Values It records the sequence multiple This data can be found in the physician notes and DDMMYYYY Date 8 21

treatment modalities discharge summary Other Treatment, Specify This information is used to evaluate and compare treatment options No Treatment, Reason Record first line treatment other than the regular upper mentioned treatment modalities, primary site oriented therapy This information helps understanding patient trends regarding conventional therapies Date at Discharge Record the reason behind the refusal treatment Helps identifying period calculation necessary for outcome evaluation and survival statistics Status at Discharge Put in the last date the patient was seen at your facility at the time reporting the case. Necessary for outcome evaluation and survival statistics put in the last patient status at your facility at the time reporting the case Permissible Values Text Permissible Values Text Permissible Values DDMMYYYY Date 8 Permissible Values Drop List 22